03/13/2026
For the first time in 9 months, the FDA is holding a cancer Advisory Committee meeting this April to discuss two AstraZeneca drugs for breast and prostate cancer.
Nuanced scientific analyses have been lacking in recent FDA "expert panels."
NCHR President Diana Zuckerman told reporters this panel should include more diversity of opinion than has been seen recently.
Cancer patients deserve rigorous, transparent reviews with solid evidence.
The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT inhibitor Truqap in prostate cancer.